Publications

MMWRs

• Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease
  September 25, 2009 / Vol 58(37);1042-43
• Report from the Advisory Committee on Immunization Practices (ACIP): Decision Not to Recommend Routine Vaccination of All Children Aged 2--10 Years with Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
  May 2, 2008 / Vol 57(17);462-465
• Emergence of fluoroquinolone-resistant Neisseria meningitidis--Minnesota and North Dakota, 2007-2008
  February 22, 2008 / Vol 57(07);173-175
• Revised ACIP Recommendations
  August 10, 2007 / Vol 56(31)
• Prevention and Control of Meningococcal Disease (ACIP Recommendations)
  May 27, 2005 / Vol. 54(RR-7)
• Serogroup W-135 Meningococcal Disease Among Travelers Returning From Saudi Arabia -- United States, 2000
  April 28, 2000 / 49(16);345-6
• CDC. Meningococcal Disease -- New England, 1993 - 1998
  July 30, 1999 / 48(29);629-633
• CDC. Change in Recommendation for Meningococcal Vaccine for Travelers (237 KB, 20 pages)
  February 12, 1999 / 48(05);104
• CDC. Lab-Based Surveillance for Meningococcal Disease -- U.S., 1989-91
  June 04, 1993 / 42(SS-2);21-30
• Control and Prevention of Meningococcal Disease and Control and Prevention of Serogroup C Meningococcal Disease: Evaluation and Management of Suspected Outbreaks
  February 14, 1997 / 46(RR-5);1-51
• Serogroup Y Meningococcal Disease -- Illinois, Connecticut, and Selected Areas, United States, 1989-1996
  November 22, 1996 / 45(46);1010-4
• Serogroup B Meningococcal Disease -- Oregon, 1994
  February 24, 1995 / 44(07);121-124

References

• Wu HM, Harcourt BH, Hatcher CP, Wei SC, Novak RT, Wang X, Juni BA, Glennen A, Boxrud DJ, Rainbow J, Schmink S, Mair RD, Theodore MJ, Sander MA, Miller TK, Kruger K, Cohn AC, Clark TA, Messonnier NE, Mayer LW, Lynfield R. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med. 2009;360:886-92.
• Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Stephens DS, and The Meningococcal Working Group. Neisseria meningitidis group B correlates of protection and assay standardization – International Meeting Report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006;24:5093-107.
• Dull P, Abdelwahab J, Sacchi C, Becker M, Noble C, Kaiser R, Mayer L, Whitney A, Schmink S, Dolan-Livengood J, Stephens DS, Ajello G, Creton M, Popovic T, Rosenstein N. Serogroup W-135 Neisseria meningitidis carriage among U.S. travelers to the 2001 Hajj. J Infect Dis 2005;191:33-9.
• Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R. Rifampin-resistant meningoccal disease. Emerg Infect Dis 2005;11(6):977-9.
• Sejvar JJ, Johnson D, Popovic T, Miller JM, Downes F, Somsel P, Weyant R, Stephens DS, Perkins B, Rosenstein NA. Assessing the risk of laboratory-acquired meningococcal disease in the United States, 1996-2000. J Clin Microbiol 2005;24:4811-4.
• Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005;115(5):1220-32.
• McEllistrem MC, Kolano JA, Pass MA, Caugant DA, Mendelsohn A, Pacheco AGF, Shutt KA, Razeq J, Harrison LH. Epidemiologic trends and genotypes causing meningococcal disease, Maryland. Emerg Infect Dis 2004;10:451-6.
• Mothershed EA, Sacchi CT, Whitney AM, et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitis. J Clin Microbiol 2004 (Jan).
• Shepard CW, Rosenstein NE, Fischer M, and the Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990-1999. Pediatr Infect Dis J, 2003;22:418-22.
• Kellerman S, McCombs K, Ray M, Farley MM, Rosenstein N, Popovic T, Blake P, Stephens DS, and the Georgia Emerging Infections Program. Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. J Infect Dis 2002;186:40-8.
• Ohuabunwo C, Bath S, Bisgard K, Murphy T, Shutt K, Rosenstein N. Progress Toward Elimination of Haemophilus influenzae Type b Invasive Disease Among Infants and Children, United States, 1998--2000. MMWR Morb Mortal Wkly Rep 2002; 51(11); 234-7.
• Rosenstein N, Perkins B, Stephens D, Popovic T, Hughes J. Meningococcal disease. NEJM 2001; 344: 1378-1388.
• Sacchi C, Whitney A, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000; 182: 1169-1176.
• CDC. Meningococcal vaccine and college students: recommendations of the Advisory Committee on Immunization Practices. MMWR 2000; 49 (RR-7): 11-20.
• Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, Chippaux J. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-1996. Bull World Health Organ 1999; 77: 499-508.
• CDC. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46 (No. RR-05): 1-21.
• Center’s for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Hemborsky J, McIntyre L, Wolfe S, eds. 10th ed. Washington DC: Public Health Foundation, 2007.
• Centers for Disease Control and Prevention. Health Information for International Travel 2008. Atlanta: US Department of Health and Human Services, Public Health Service, 2007.

Chapters

• Epidemiology and Prevention of Vaccine-Preventable Diseases: Meningococcal Disease (Also called the Pink Book) (711 KB, 12 pages)
  Describes meningococcal disease, the Neisseria meningitidis bacteria, pathogenesis, clinical features, complications, laboratory diagnosis, medical management, epidemiology, secular trends, meningococcal vaccines, vaccination schedule and use, contraindications and precautions to vaccination, adverse reactions following vaccination, vaccine storage and handling, and antimicrobial chemoprophylaxis.
• Travelers’ Health: Yellow Book
  Meningococcal Disease chapter from CDC’s Health Information for International Travel 2010 (Prevention of Specific Infectious Diseases). Describes the occurrence, risk for travelers, clinical presentation, prevention, and treatment of meningococcal disease.
• Surveillance Manual – Chapter 8: Meningococcal Disease Manual for the Surveillance of Vaccine-Preventable Diseases (4th Edition, 2008). Describes the disease, background, importance of rapid identification and surveillance, disease reduction goals, case definition, laboratory testing, reporting, vaccination, enhancing surveillance, case investigation, and outbreaks.